The effect of prescription and over-the-counter medications on core temperature in adults during heat stress: a systematic review and meta-analysis.

IF 9.6 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL EClinicalMedicine Pub Date : 2024-10-24 eCollection Date: 2024-11-01 DOI:10.1016/j.eclinm.2024.102886
Lily Hospers, Gabrielle A Dillon, Andrew J McLachlan, Lacy M Alexander, W Larry Kenney, Anthony Capon, Kristie L Ebi, Edward Ashworth, Ollie Jay, Yorgi Mavros
{"title":"The effect of prescription and over-the-counter medications on core temperature in adults during heat stress: a systematic review and meta-analysis.","authors":"Lily Hospers, Gabrielle A Dillon, Andrew J McLachlan, Lacy M Alexander, W Larry Kenney, Anthony Capon, Kristie L Ebi, Edward Ashworth, Ollie Jay, Yorgi Mavros","doi":"10.1016/j.eclinm.2024.102886","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Heat stress impacts are an escalating global health concern. Public health bodies such as the World Health Organization (WHO) warn that certain medications impair thermoregulation, with limited supporting evidence. Our aim was to investigate whether medications listed by the WHO increase core temperature responses during heat stress.</p><p><strong>Methods: </strong>For this systematic review and meta-analysis, MEDLINE, PubMed, Scopus, CINAHL, Web of Science, and EMBASE were searched up to Jan.30, 2024. Randomised studies exposing humans to exertional and/or passive heat stress that investigated a drug identified by WHO compared to no drug/placebo were eligible. The primary outcome was core temperature (e.g., rectal, oesophageal, aural, tympanic). We assessed risk of bias (Cochrane's Risk of Bias 2) and certainty of evidence (GRADE). The study was pre-registered on PROSPERO (CRD42020170684).</p><p><strong>Findings: </strong>Thirty-five studies were included enrolling 353 individuals (16 women; 4.5%). Twenty-seven unique medications were tested. The average age of participants across studies was <30 years, and only one study included a clinical population. Under heat stress, there was moderate quality evidence that drugs with high anticholinergic properties increased core temperature at air temperatures ≥30°C (+0.42°C; 95% CI 0.04, 0.79°C; p = 0.03) alongside reduced sweating, although evidence is limited to the drug atropine. Similarly, non-selective beta-blockers (+0.11°C; 95% CI 0.02, 0.19°C; p = 0.02), adrenaline (+0.41°C; 95% CI 0.21, 0.61°C) and anti-Parkinson's agents (+0.13°C; 95% CI 0.07, 0.19°C; p = 0.02) elevated core temperature. Antidepressants, diuretics, or drugs with weak anticholinergic effects did not alter core temperature responses.</p><p><strong>Interpretation: </strong>Current evidence supports strong anticholinergics, non-selective beta-blockers, adrenaline, and anti-Parkinson's agents impairing thermoregulation during heat stress. No evidence indicated thermoregulation is impacted by other WHO-listed medications. Evidence is predominantly limited to healthy young men, with short heat stress exposures. Studies over longer durations, in women, older adults and those with chronic diseases are required to better inform the pharmaceutical management of patients during hot weather.</p><p><strong>Funding: </strong>This study was supported by a National Health and Medical Research Council (NHMRC) Investigator Grant (2021/GNT2009507; Holder: O. Jay).</p>","PeriodicalId":11393,"journal":{"name":"EClinicalMedicine","volume":null,"pages":null},"PeriodicalIF":9.6000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11541675/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EClinicalMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eclinm.2024.102886","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Heat stress impacts are an escalating global health concern. Public health bodies such as the World Health Organization (WHO) warn that certain medications impair thermoregulation, with limited supporting evidence. Our aim was to investigate whether medications listed by the WHO increase core temperature responses during heat stress.

Methods: For this systematic review and meta-analysis, MEDLINE, PubMed, Scopus, CINAHL, Web of Science, and EMBASE were searched up to Jan.30, 2024. Randomised studies exposing humans to exertional and/or passive heat stress that investigated a drug identified by WHO compared to no drug/placebo were eligible. The primary outcome was core temperature (e.g., rectal, oesophageal, aural, tympanic). We assessed risk of bias (Cochrane's Risk of Bias 2) and certainty of evidence (GRADE). The study was pre-registered on PROSPERO (CRD42020170684).

Findings: Thirty-five studies were included enrolling 353 individuals (16 women; 4.5%). Twenty-seven unique medications were tested. The average age of participants across studies was <30 years, and only one study included a clinical population. Under heat stress, there was moderate quality evidence that drugs with high anticholinergic properties increased core temperature at air temperatures ≥30°C (+0.42°C; 95% CI 0.04, 0.79°C; p = 0.03) alongside reduced sweating, although evidence is limited to the drug atropine. Similarly, non-selective beta-blockers (+0.11°C; 95% CI 0.02, 0.19°C; p = 0.02), adrenaline (+0.41°C; 95% CI 0.21, 0.61°C) and anti-Parkinson's agents (+0.13°C; 95% CI 0.07, 0.19°C; p = 0.02) elevated core temperature. Antidepressants, diuretics, or drugs with weak anticholinergic effects did not alter core temperature responses.

Interpretation: Current evidence supports strong anticholinergics, non-selective beta-blockers, adrenaline, and anti-Parkinson's agents impairing thermoregulation during heat stress. No evidence indicated thermoregulation is impacted by other WHO-listed medications. Evidence is predominantly limited to healthy young men, with short heat stress exposures. Studies over longer durations, in women, older adults and those with chronic diseases are required to better inform the pharmaceutical management of patients during hot weather.

Funding: This study was supported by a National Health and Medical Research Council (NHMRC) Investigator Grant (2021/GNT2009507; Holder: O. Jay).

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
处方药和非处方药对成人热应激时核心体温的影响:系统综述和荟萃分析。
背景:热应激影响是一个不断升级的全球健康问题。世界卫生组织(WHO)等公共卫生机构警告说,某些药物会损害体温调节功能,但相关证据却很有限。我们的目的是调查世界卫生组织列出的药物是否会增加热应激时的核心体温反应:为了进行这项系统综述和荟萃分析,我们检索了截至 2024 年 1 月 30 日的 MEDLINE、PubMed、Scopus、CINAHL、Web of Science 和 EMBASE。符合条件的随机研究包括将人体暴露于外力和/或被动热应激状态,并对世卫组织确定的药物与无药/安慰剂进行比较的研究。主要结果为核心体温(如直肠、食道、耳、鼓膜)。我们评估了偏倚风险(Cochrane 的偏倚风险 2)和证据的确定性(GRADE)。该研究已在 PROSPERO 上预先注册(CRD42020170684):共有 35 项研究纳入了 353 人(女性 16 人,占 4.5%)。测试了 27 种独特的药物。各研究参与者的平均年龄为 15 岁:目前有证据表明,强效抗胆碱能药、非选择性β-受体阻滞剂、肾上腺素和抗帕金森氏症药会在热应激时损害体温调节功能。没有证据表明世卫组织列出的其他药物会影响体温调节。证据主要局限于健康的年轻男性和短时间的热应激暴露。需要对女性、老年人和慢性病患者进行更长时间的研究,以便更好地为高温天气下的患者药物管理提供信息:本研究得到了美国国家健康与医学研究委员会(NHMRC)调查员补助金(2021/GNT2009507;持有人:O. Jay)的支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
EClinicalMedicine
EClinicalMedicine Medicine-Medicine (all)
CiteScore
18.90
自引率
1.30%
发文量
506
审稿时长
22 days
期刊介绍: eClinicalMedicine is a gold open-access clinical journal designed to support frontline health professionals in addressing the complex and rapid health transitions affecting societies globally. The journal aims to assist practitioners in overcoming healthcare challenges across diverse communities, spanning diagnosis, treatment, prevention, and health promotion. Integrating disciplines from various specialties and life stages, it seeks to enhance health systems as fundamental institutions within societies. With a forward-thinking approach, eClinicalMedicine aims to redefine the future of healthcare.
期刊最新文献
Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial. Non-invasive prediction of human embryonic ploidy using artificial intelligence: a systematic review and meta-analysis. Response to Campbell et al.'s comments on our study "Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study". The effect of prescription and over-the-counter medications on core temperature in adults during heat stress: a systematic review and meta-analysis. Risk factors associated with post-tuberculosis sequelae: a systematic review and meta-analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1